Literature DB >> 34130003

Feature engineering and machine learning for causality assessment in pharmacovigilance: Lessons learned from application to the FDA Adverse Event Reporting System.

Kory Kreimeyer1, Oanh Dang2, Jonathan Spiker1, Monica A Muñoz2, Gary Rosner1, Robert Ball2, Taxiarchis Botsis3.   

Abstract

BACKGROUND: Our objective was to support the automated classification of Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) reports for their usefulness in assessing the possibility of a causal relationship between a drug product and an adverse event.
METHOD: We used a data set of 326 redacted FAERS reports that was previously annotated using a modified version of the World Health Organization-Uppsala Monitoring Centre criteria for drug causality assessment by a group of SEs at the FDA and supported a similar study on the classification of reports using supervised machine learning and text engineering methods. We explored many potential features, including the incorporation of natural language processing on report text and information from external data sources, for supervised learning and developed models for predicting the classification status of reports. We then evaluated the models on a larger data set of previously unseen reports.
RESULTS: The best-performing models achieved recall and F1 scores on both data sets above 0.80 for the identification of assessable reports (i.e. those containing enough information to make an informed causality assessment) and above 0.75 for the identification of reports meeting at least a Possible causality threshold.
CONCLUSIONS: Causal inference from FAERS reports depends on many components with complex logical relationships that are yet to be made fully computable. Efforts focused on readily addressable tasks, such as quickly eliminating unassessable reports, fit naturally in SE's thought processes to provide real enhancements for FDA workflows.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Keywords:  Case classification; Causality assessment; Clinical natural language processing; Decision support; Pharmacovigilance

Year:  2021        PMID: 34130003     DOI: 10.1016/j.compbiomed.2021.104517

Source DB:  PubMed          Journal:  Comput Biol Med        ISSN: 0010-4825            Impact factor:   4.589


  7 in total

1.  Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.

Authors:  Yauheniya Cherkas; Joshua Ide; John van Stekelenborg
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.606

2.  The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature.

Authors:  Maribel Salas; Jan Petracek; Priyanka Yalamanchili; Omar Aimer; Dinesh Kasthuril; Sameer Dhingra; Toluwalope Junaid; Tina Bostic
Journal:  Pharmaceut Med       Date:  2022-07-29

Review 3.  Machine Learning in Causal Inference: Application in Pharmacovigilance.

Authors:  Yiqing Zhao; Yue Yu; Hanyin Wang; Yikuan Li; Yu Deng; Guoqian Jiang; Yuan Luo
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

4.  Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance.

Authors:  Raymond Kassekert; Neal Grabowski; Denny Lorenz; Claudia Schaffer; Dieter Kempf; Promit Roy; Oeystein Kjoersvik; Griselda Saldana; Sarah ElShal
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

5.  "Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time?

Authors:  Robert Ball; Gerald Dal Pan
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

6.  Challenges and opportunities for mining adverse drug reactions: perspectives from pharma, regulatory agencies, healthcare providers and consumers.

Authors:  Graciela Gonzalez-Hernandez; Martin Krallinger; Monica Muñoz; Raul Rodriguez-Esteban; Özlem Uzuner; Lynette Hirschman
Journal:  Database (Oxford)       Date:  2022-09-02       Impact factor: 4.462

7.  Editorial: Leveraging pharmacovigilance data mining with "the patient" in mind.

Authors:  Maxine Gossell-Williams; Maribel Salas
Journal:  Front Pharmacol       Date:  2022-08-15       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.